Janux Therapeutics (NASDAQ:JANX) Releases Earnings Results, Beats Expectations By $0.14 EPS

Janux Therapeutics (NASDAQ:JANX) posted its earnings results on Thursday. The company reported ($0.51) earnings per share for the quarter, beating the consensus estimate of ($0.65) by $0.14, FiscalAI reports. The firm had revenue of $7.88 million during the quarter, compared to analyst estimates of $0.08 million.

Janux Therapeutics Trading Down 1.8%

JANX stock traded down $0.25 during trading on Friday, hitting $13.55. The company had a trading volume of 303,870 shares, compared to its average volume of 1,417,589. The business has a 50 day moving average of $13.73 and a 200 day moving average of $20.80. The firm has a market capitalization of $815.03 million, a price-to-earnings ratio of -8.06 and a beta of 2.88. Janux Therapeutics has a fifty-two week low of $12.12 and a fifty-two week high of $35.34.

Insider Buying and Selling at Janux Therapeutics

In other news, insider Andrew Hollman Meyer sold 1,879 shares of the firm’s stock in a transaction on Friday, January 2nd. The stock was sold at an average price of $13.73, for a total transaction of $25,798.67. Following the completion of the sale, the insider directly owned 83,095 shares of the company’s stock, valued at $1,140,894.35. This trade represents a 2.21% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, insider Thomas Diraimondo sold 2,505 shares of the company’s stock in a transaction on Friday, January 2nd. The shares were sold at an average price of $13.73, for a total value of $34,393.65. Following the transaction, the insider directly owned 124,425 shares in the company, valued at $1,708,355.25. The trade was a 1.97% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last quarter, insiders sold 22,366 shares of company stock valued at $371,245. Corporate insiders own 8.10% of the company’s stock.

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in JANX. AQR Capital Management LLC grew its position in Janux Therapeutics by 71.7% in the first quarter. AQR Capital Management LLC now owns 9,717 shares of the company’s stock valued at $262,000 after acquiring an additional 4,059 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its holdings in Janux Therapeutics by 18.8% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 21,403 shares of the company’s stock worth $583,000 after purchasing an additional 3,393 shares during the period. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC boosted its holdings in shares of Janux Therapeutics by 12.5% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 186,394 shares of the company’s stock valued at $5,033,000 after buying an additional 20,657 shares during the period. JPMorgan Chase & Co. boosted its position in Janux Therapeutics by 82.9% during the 2nd quarter. JPMorgan Chase & Co. now owns 247,424 shares of the company’s stock worth $5,715,000 after acquiring an additional 112,116 shares during the last quarter. Finally, Legal & General Group Plc grew its holdings in shares of Janux Therapeutics by 12.0% in the 2nd quarter. Legal & General Group Plc now owns 47,353 shares of the company’s stock valued at $1,094,000 after acquiring an additional 5,055 shares in the last quarter. Institutional investors and hedge funds own 75.39% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research analysts have recently commented on JANX shares. Clear Str downgraded Janux Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Tuesday, January 20th. Cantor Fitzgerald cut their price target on shares of Janux Therapeutics from $150.00 to $100.00 and set an “overweight” rating for the company in a report on Friday. Guggenheim decreased their price objective on shares of Janux Therapeutics from $72.00 to $68.00 and set a “buy” rating on the stock in a research report on Friday. UBS Group reiterated a “buy” rating and set a $57.00 target price on shares of Janux Therapeutics in a report on Tuesday, December 2nd. Finally, Bank of America dropped their target price on Janux Therapeutics from $58.00 to $49.00 and set a “buy” rating for the company in a research note on Tuesday, December 2nd. Eleven equities research analysts have rated the stock with a Buy rating, three have given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, Janux Therapeutics currently has an average rating of “Moderate Buy” and a consensus price target of $55.58.

About Janux Therapeutics

Janux Therapeutics is a clinical-stage biotechnology company focused on developing next-generation intratumoral immuno-oncology therapies that harness the body’s innate and adaptive immune systems. The company designs and synthesizes proprietary Toll-like receptor (TLR) agonists to reprogram the tumor microenvironment. Janux is publicly traded on the Nasdaq under the symbol JANX.

Its lead programs include JTX-8064, a fully synthetic TLR4 agonist engineered for optimal stability and potency, and JTX-4014, a TLR1/2 agonist formulated for direct intratumoral administration.